CRF Health has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study. CRF Health's TrialMax Touch handheld device alone with other solutions will be utilized to collect quality of life readings and alleviate the burden of data entry for caOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.